# Regulation of Macrophage- and Microglia-mediated STING Signaling in Glioblastoma

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $387,254

## Abstract

Glioblastoma is the most common primary malignant brain tumor in adults with a median survival of less than
15 months despite aggressive standard of care including surgery, radiation and chemotherapy. Novel therapies
are therefore in critical need. Tumor-derived 2′3′-Cyclic GMP-AMP (cGAMP) induced by chemotherapy and
radiation activates STING in myeloid cells as an immunotransmitter to elicit anti-tumor response. Macrophages
and microglia are both potent responder to cGAMP in non-tumor conditions, however, in GBM, macrophages
and microglia, which are one of the most abundant cells in the tumor microenvironment, are profoundly
immunosuppressive. It is unclear through what molecular mechanisms and fundamental biology that
macrophages and microglia minimize STING activation in GBM. While STING signaling is activated by a series
of well-characterized protein phosphorylation, the mechanisms of inactivation/dephosphorylation of STING
signaling is unclear. Protein phosphatase 2A (PP2A) is a ubiquitous serine/threonine phosphatase comprised of
a catalytic (C), regulatory (B) and scaffolding (A) subunit and accounts for 50-70% of the total serine/threonine
phosphatase activity. The specificity of PP2A is determined by its regulatory B subunit. We have found that
inhibition of PP2A catalytic subunit (PP2Ac) in both macrophages and microglia enhances STING signaling.
Mice with macrophages/microglia specific deletion of PP2Ac have increased tumor T cells infiltration and
reduced tumor growth. Moreover, from unbiased screening of all known regulatory B subunits, we find that
striatin4, a specific B subunit of PP2A, has a similar role as PP2Ac in suppressing STING signaling in
macrophages/microglia but not in glioma cells. In this project, we propose to: Aim 1) Determine the impact of
PP2Ac inhibition in macrophages/microglia on STING pathway in glioma microenvironment in vivo. Aim 2)
Elucidate the molecular mechanisms underlying STING inhibition by striatin4-PP2Ac complex in
macrophages/microglia. We will also use clinically annotated GBM samples to verify the clinical relevance of
striatin4-PP2A. These findings will firmly establish the role of the specific striatin4-PP2A complex in regulating
macrophage/microglia functions and also provide the mechanistic foundation to target this specific PP2A
complex leading to precise targeting of PP2A as a novel therapy for glioma. This proposed study will also address
the fundamental biology about how glioma cells and macrophages/microglia communicate through cGAMP and
how macrophage/microglia turn off STING activation through PP2A. We appreciate that PP2A complexes play
significant roles not only in macrophages/microglia, but also in glioma cells and other cell types. Our long-term
goal is to identify the specific PP2A complexes in glioma cells, immune cells, astrocytes and other cell types within
the central neural system relevant to the modulation of immune response in order to develop novel therapeutics
for GBM. We...

## Key facts

- **NIH application ID:** 10691224
- **Project number:** 5R01NS126501-02
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Rongze Olivia Lu
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $387,254
- **Award type:** 5
- **Project period:** 2022-09-01 → 2027-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10691224

## Citation

> US National Institutes of Health, RePORTER application 10691224, Regulation of Macrophage- and Microglia-mediated STING Signaling in Glioblastoma (5R01NS126501-02). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10691224. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*